The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

Sperm gurus & biotech tries to tackle coronavirus

By Meghana Keshavan

The READOUT
The Readout

Layoffs at 23andMe & mega-bucks for pricing lobbyists

By Meghana Keshavan

The READOUT
The Readout

Sarepta’s endless saga & Insys execs go to prison

By Damian Garde

The READOUT
The Readout

Biogen at Davos & that therapeutic video game

By Damian Garde

The READOUT
The Readout

A new pan-cancer target & repurposing 200ish drugs

By Meghana Keshavan

The READOUT
The Readout

Microglia as an Alzheimer’s target & FTC chief contradicts party on Medicare

By Meghana Keshavan

The READOUT
The Readout

VCs warm to brain diseases, Verily steps on a few toes, & do you even shroom, bro?

By Damian Garde

The READOUT
The Readout

Regeneron’s Yancopoulos is a bit bitter, Vivian Lee’s path to Verily, & JPM in a minor key

By Damian Garde

The READOUT
The Readout

An interview with GSK’s Walmsley, showtime for NASH drugs, & Biogen still bullish

By Damian Garde

The READOUT
The Readout

A curious Union Square billboard, M&A MIA, & Biomarin’s plot to dominate

By Damian Garde

The READOUT
The Readout

A ‘radical proposition’ for biotech & Jackie Fouse’s JPM debut

By Damian Garde

The READOUT
The Readout

23andMe licenses a home-grown drug & a Solid restructuring

By Meghana Keshavan

The READOUT
The Readout

Happy 20th to JPM & what is Celgene doing?

By Damian Garde

The READOUT
The Readout

Soon-Shiong’s earthbound ‘moonshot’ & Alexion’s future in rare disease

By Damian Garde

The READOUT
The Readout

The next Chinese biotech IPO & why CREATES is ominous

By Damian Garde

The READOUT
The Readout

December approval concerns & your questions for the outgoing Gates Foundation CEO

By Meghana Keshavan

The READOUT
The Readout

Wave disappoints & Illumina pulls the plug on a merger

By Meghana Keshavan

The READOUT
The Readout

The most important drugs of the 2010s & a preview of 2020’s biotech events

By Damian Garde

The READOUT
The Readout

HER2 and FDA’s many fast approvals & scaling CAR-T and its ilk

By Meghana Keshavan

The READOUT
The Readout

2019’s best and worst CEOs & Novartis’ gene therapy lottery

By Damian Garde

The READOUT
The Readout

Bad biotech predictions & Woodford’s Chinese sojourn

By Damian Garde

The READOUT
The Readout

Gene therapy’s big hindrance & Illumina’s antitrust woes

By Damian Garde

The READOUT
The Readout

Roche-Spark deal cleared & the VC fund giving money away

By Damian Garde

The READOUT
The Readout

Amarin wins expanded approval & Gilead’s major CAR-T loss

By Damian Garde

The READOUT
The Readout

FDA reverses Sarepta’s rejection & Alector finds a new idea in Alzheimer’s

By Damian Garde

The READOUT
The Readout

A big vote on drug pricing & good news in breast cancer

By Damian Garde

The READOUT
The Readout

Pharma trips up on trade policy & biotech looks buyable

By Damian Garde

The READOUT
The Readout

Billions in biotech buyouts & CAR-T’s uncertain future

By Damian Garde

The READOUT
The Readout

What’s up at ASH & the price of two sickle cell drugs

By Meghana Keshavan

Your daily dose of news in health and medicine

Privacy Policy